26/10/2026 EMVision Medical Devices Ltd ACN 620 388 230 Suite 4.01, 65 Epping Rd Sydney NSW 2113 02 8667 5337 contact@emvision.com.au APPENDIX 4C – 30 SEPTEMBER 2026 QUARTERLY ACTIVITIES & CASHFLOW REPORT Highlights • By early October, the Pivotal (Validation) trial surpassed 230 patients...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 12 pages · English
Summary by 6ix AI
Emvision maintains a strong financial position with cash reserves increasing from the previous quarter, supporting ongoing clinical and regulatory milestones. The company has signed a memorandum of understanding with the Australian Stroke Alliance to pursue funding for pre-hospital stroke diagnosis research.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- Notice of Annual General Meeting/Proxy Form
- Mayo Clinic emu Early Clinical Experience Presentation
- Date of AGM & Closing Date of Director Nominations
- $4.3m Non-Dilutive R&D Tax Rebate Received
- First Responder Successfully Trialled with MSU
Later from EMvision Medical Devices
All EMvision Medical Devices news releasesFollow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices